Phase II study of metastatic melanoma using lymphodepleting conditioning followed by infusion of anti-gp 100: 154-162 TCR-gene engineered lymphocytes [gp100-specific T lymphocyte-therapy] and ALVAC virus immunization [ALVAC-CEA].

Trial Profile

Phase II study of metastatic melanoma using lymphodepleting conditioning followed by infusion of anti-gp 100: 154-162 TCR-gene engineered lymphocytes [gp100-specific T lymphocyte-therapy] and ALVAC virus immunization [ALVAC-CEA].

Discontinued
Phase of Trial: Phase II

Latest Information Update: 02 Nov 2015

At a glance

  • Drugs ALVAC CEA (Primary) ; Gp100-specific T lymphocyte therapy (Primary) ; Aldesleukin; Cyclophosphamide; Fludarabine
  • Indications Malignant melanoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 09 Apr 2012 Planned end date changed from 1 Jan 2011 to 1 Feb 2011 as reported by ClinicalTrials.gov.
    • 09 Apr 2012 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
    • 28 Feb 2011 Actual end date (Feb 2011) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top